Insulet PODD · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
149.81
+2.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Insulet
From its filings with the US Securities and Exchange Commission
Insulet is based in Acton, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PODD. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $2.71bn and net income of $247.1m. At that date it held total assets of $3.19bn and shareholders' equity of $1.52bn. By region, U.S. accounted for 72.2%, followed by International at 27.9%.
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).
We also produce pods for Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia. Hyperglycemia can lead to serious short-term complications, such as confusion, vomiting, dehydration, and loss of consciousness and long-term complications, such as blindness, kidney disease, nervous system disease, occlusive vascular diseases, stroke, cardiovascular disease, or death. Hypoglycemia can lead to confusion, loss of consciousness, or death.
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 15 May 2007
- Employees
- 5,400
- Website
- myomnipod.com ↗
- Head office
- 100 NAGOG PARK, ACTON, MA, 01720
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Timothy ScannellIndependent Chairman of the Board$414,354
- Ms. Ashley McevoyPresident, Chief Executive Officer, Director, since 2025
- Ms. Flavia PeaseChief Financial Officer, Executive Vice President, since 2024$602,925
- Mr. Eric BenjaminChief Operating Officer$4.1m
- Mr. Dan ManeaChief Human Resources Officer, Senior Vice President$1.7m
- Mr. John KapplesSenior Vice President, General Counsel$2.9m
- Ms. Laetitia CousinSenior Vice President - Regulatory Affairs, Quality Assurance and Compliance
- Mr. Prem SinghSenior Vice President - Global Operations
- Mr. Amit GulianiActing Chief Technology Officer, Group Vice President - Software Engineering
- Ms. Lauren BuddenChief Accounting Officer, Group Vice President, Corporate Controller$1.6m
- Mr. Manoj RaghunandananChief Growth Officer
- Dr. Luciana BorioIndependent Director$318,461
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 64
- Social
- 94
- Governance
- 64
- Direct emissions (scope 1)
- 1,383 t
- Energy emissions (scope 2)
- 11,057 t
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Insulet Corp has developed a highly innovative technology in the form of its tubeless insulin delivery system known as the Omnipod. This technology provides significant benefits to diabetic patients, such as increased convenience, freedom, and improved glycemic control. The Omnipod's unique design has positioned the company as a market leader in the insulin pump industry.
- Insulet Corp has established a strong market presence, with its products being widely recognized and accepted within the healthcare industry. This has enabled the company to secure partnerships with major insurers and healthcare providers, further enhancing its market position and ensuring steady revenue streams.
Weaknesses
- Insulet Corp heavily relies on the success of its Omnipod system, as it is the company's primary source of revenue. While the technology has proven to be highly effective, any potential issues or competition in the market could significantly impact Insulet Corp's financial performance. Diversification of product offerings may be necessary to mitigate this weakness.
- Despite its strong market presence in certain regions, Insulet Corp's global reach is relatively limited. The company primarily operates in North America, which exposes it to potential market saturation and barriers to international growth. Expanding into new markets and regions would help Insulet Corp diversify its customer base and decrease its dependence on a single market.
Opportunities
- The global diabetic population is on the rise, creating a significant opportunity for Insulet Corp. As more individuals require insulin delivery systems, the demand for the company's innovative technology is expected to increase. Insulet Corp can capitalize on this growing market by expanding its product offerings and marketing efforts to reach a larger customer base.
- The rapid advancements in connected devices and the Internet of Things (IoT) present an opportunity for Insulet Corp to enhance its insulin delivery system. By incorporating connectivity features and leveraging data analytics, the company can provide more personalized and effective solutions for diabetic patients. This would not only improve patient experience but also drive customer loyalty and market differentiation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.